Iperion Limited Analysis

Overview

Iperion Limited (formally Southern Charter Financial Group Limited) is in the process of commercializing a novel antimicrobial coating product, being marketed under the name Pathoglaze. Early in 2023 Iperion entered into a license agreement granting the company an exclusive, worldwide, sub-licensable licence to manufacture, use, sell, distribute, import and export a self-cleaning, transparent, antimicrobial, surface coating product. A pilot manufacturing facility has since been established in Malaysia. The manufacturing facility and production is fully outsourced. The company is now actively marketing Pathoglaze.

Prior to 2023 the company did not have an operating business, but was searching for and investigating opportunities for acquiring a new business. This followed the completion of transactions on 31 August 2017 that injected cash, introduced a new controlling shareholder and spun-out all previous assets, liabilities and business operations.

Performance

The following information was extracted from Iperion Limited's half year results, released 29 May 2026

Financial Results

The Company reported a net loss attributable to shareholders of $294,595 for the year. This compares with a net loss attributable to shareholders of $455,683 for the previous year.

There was no sales income for the year. The improvement in result compared to the previous year is mainly a result of discount received on the fixed outsourced manufacturing plant fee.

There were no manufacturing plant expenses for the year. The vendor agreed to discount the $400,000 fixed annual fees for the two financial years ending 31 March 2026 and 31 March 2027 in recognition of lower than expected production activity and the plant being partially supported by research grants secured by the operator on the ongoing development in applications for the Pathoglaze® product.

Administrative expenses for the year were $294,605 decreasing by $23,176 on the prior year. Expenses remained mostly in line with the previous year, except for higher stock exchange costs and lower costs on travel in the year.